Form 8-K - Current report:
SEC Accession No. 0000950170-25-045232
Filing Date
2025-03-26
Accepted
2025-03-26 16:12:47
Documents
12
Period of Report
2025-03-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crsp-20250324.htm   iXBRL 8-K 51523
2 EX-99.1 crsp-ex99_1.htm EX-99.1 8217
  Complete submission text file 0000950170-25-045232.txt   174927

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20250324.xsd EX-101.SCH 25984
14 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20250324_htm.xml XML 4500
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37923 | Film No.: 25773310
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)